HRT and menopause: 15 example statics

Ovelle logo (spec brand)

15 statics for one spec brand, three for each awareness stage.

Unaware

Problem aware

Solution aware

Product aware

Most aware

How this batch was built

Each static starts from one angle on the HRT and menopause angles page and one awareness stage. The stage decides what the viewer already knows; the angle decides the desire and the objection the ad answers; the format decides how it looks in the feed. Ovelle is a made-up spec brand, so nothing here is a real offer.

  • HRT-ST-01: a three stacked timeline cards static for the unaware stage, running the “The study everyone remembers” angle, written for the desire “know what the february 2026 label change says” and the objection “The warning I remember”.
  • HRT-ST-02: a email inbox static for the unaware stage, running the “The study everyone remembers” angle, written for the desire “know what the february 2026 label change says” and the objection “The warning I remember”.
  • HRT-ST-03: a in / out split static for the unaware stage, running the “The study everyone remembers” angle, written for the desire “know what the february 2026 label change says” and the objection “The warning I remember”.
  • HRT-ST-04: a giant stacked type + photo static for the problem aware stage, running the “Told it was stress” angle, written for the desire “being taken seriously” and the objection “My doctor said it was stress”.
  • HRT-ST-05: a phone notes timestamped log static for the problem aware stage, running the “3am wake-ups” angle, written for the desire “sleep through the night” and the objection “It's just how it is now”.
  • HRT-ST-06: a photo + 'confused about...' + quiz button static for the problem aware stage, running the “Talk about it at dinner” angle, written for the desire “normalize” and the objection “Nobody talks about this”.
  • HRT-ST-07: a headline + product + pill labels static for the solution aware stage, running the “A provider who specializes” angle, written for the desire “be taken seriously” and the objection “My doctor brushed it off”.
  • HRT-ST-08: a minimal premium statement static for the solution aware stage, running the “Not for everyone” angle, written for the desire “safety” and the objection “They'll give it to anyone”.
  • HRT-ST-09: a 'this one sucks / get one that doesn't' two photo static for the solution aware stage, running the “A provider who specializes” angle, written for the desire “be taken seriously” and the objection “My doctor brushed it off”.
  • HRT-ST-10: a product in hand + chat bubbles static for the product aware stage, running the “Patch, cream or pill” angle, written for the desire “choice” and the objection “I don't want pills”.
  • HRT-ST-11: a stacked label chips over photo static for the product aware stage, running the “Ongoing check-ins” angle, written for the desire “support” and the objection “They'll forget me”.
  • HRT-ST-12: a apology letter on solid color static for the product aware stage, running the “What the intake asks” angle, written for the desire “know before starting” and the objection “I don't know what they'll ask”.
  • HRT-ST-13: a editorial 'we're open' with hours block static for the most aware stage, running the “No waiting list” angle, written for the desire “speed” and the objection “Specialists have long waits”.
  • HRT-ST-14: a 'your new favorite' product + button static for the most aware stage, running the “No waiting list” angle, written for the desire “speed” and the objection “Specialists have long waits”.
  • HRT-ST-15: a quote banner over product static for the most aware stage, running the “No waiting list” angle, written for the desire “speed” and the objection “Specialists have long waits”.
  1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. Source
  2. Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. Source
  3. FDA, "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products", 12 February 2026: labeling changes approved for six products, removing the cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warning. Source

Videos in this batch

Back to the HRT and menopause overview.

Same page for other verticals

Related reading

All brands shown are spec concepts made by Telehealth Media. They are not real companies.

Ready for your first batch?

Book a call